You are not logged in.

Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials

Gao, L., Zhao, F.-L. and Li, S.-C. 2012, Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials, Experimental and clinical endocrinology & diabetes, vol. 120, no. 06, pp. 367-375, doi: 10.1055/s-0032-1304619.


Title Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials
Author(s) Gao, L.
Zhao, F.-L.
Li, S.-C.
Journal name Experimental and clinical endocrinology & diabetes
Volume number 120
Issue number 06
Start page 367
End page 375
Total pages 9
Publisher Thieme
Place of publication Stuttgart, Germany
Publication date 2012-06
ISSN 0947-7349
1439-3646
Keyword(s) Polycystic Ovary Syndrome (PCOS)
hydroxymethylglutaryl-CoA reductase inhibitors
meta-analysis
Summary Objectives: To date no consensus has been reached on whether to administer statin to patients with Polycystic Ovary Syndrome (PCOS) routinely. Therefore, we conduct a meta-analysis to synthesize the literatures regarding therapeutic effects of statins on PCOS.

Methods: A comprehensive literature search was performed using terms such as polycystic ovary syndrome, ovary polycystic disease, PCOS, hyperandrogaenemia; simvastatin, atorvastatin, lipidemic-modulating drugs, lipid lowering drugs, and testosterone; randomized controlled trials in the following bibliographic databases: Medline, Embase, Cochrane Controlled Trials Register. Identified reference lists were checked manually.

Results: In total, 4 RCTs were included. 3 of 4 studies were double-blinded while none reported whether of the data was analyzed using intention-to-treat analysis. Serum total testosterone and lipid profiles were included as investigation outcomes. Differences in reducing serum total testosterone were observed when comparing statin with placebo (Std MD= − 3.03, 95%CI − 5.85 ~ − 0.22, P=0.03) or statin + metformin with metformin (Std MD=− 1.07, 95%CI: − 2.06~ − 0.07, P=0.04). Heterogeneities were detected in both comparisons (I2=96% and 88% respectively). Meanwhile, statin was more effective than placebo in reducing LDL (WMD=− 0.87, 95%CI  − 1.18~ − 0.55, P<0.0001), TC (WMD=− 1.23 95%CI  − 1.35~ − 1.11, P<0.00001), TG (WMD= − 0.50, 95%CI  − 0.73~ − 0.27, P<0.00001); and statin + metformin was more effective than metformin in lowering LDL (WMD= − 0.84, 95%CI:  − 1.33 ~ − 0.354, P=0.0009), TC (WMD= − 1.28, 95%CI: − 1.47 ~ − 1.10, P<0.00001), and TG (WMD= − 0.27, 95%CI:  − 0.36~ − 0.19, P<0.00001). Heterogeneities were detected during the meta-analysis.

Conclusions: Statins can reduce the concentration of total testosterone, TC, TG and LDL. However, it cannot be concluded that statins have long-term benefit. A large-scale, randomized controlled study is needed to ascertain this uncertainty.
Language eng
DOI 10.1055/s-0032-1304619
Field of Research 110399 Clinical Sciences not elsewhere classified
1103 Clinical Sciences
Socio Economic Objective 920507 Women's Health
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2012, Georg Thieme Verlag
Persistent URL http://hdl.handle.net/10536/DRO/DU:30087044

Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 23 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 6 Abstract Views  -  Detailed Statistics
Created: Wed, 12 Oct 2016, 10:59:04 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.